FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:DPM1-CYP4F12

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: DPM1-CYP4F12
FusionPDB ID: 23973
FusionGDB2.0 ID: 23973
HgeneTgene
Gene symbol

DPM1

CYP4F12

Gene ID

8813

66002

Gene namedolichyl-phosphate mannosyltransferase subunit 1, catalyticcytochrome P450 family 4 subfamily F member 12
SynonymsCDGIE|MPDSCYPIVF12|F22329_1
Cytomap

20q13.13

19p13.12

Type of geneprotein-codingprotein-coding
Descriptiondolichol-phosphate mannosyltransferase subunit 1DPM synthase complex, catalytic subunitDPM synthase subunit 1MPD synthase subunit 1dolichol monophosphate mannose synthasedolichol-phosphate mannose synthase subunit 1dolichyl-phosphate beta-D-mannosylcytochrome P450 4F12cytochrome P450, family 4, subfamily F, polypeptide 12cytochrome P450, subfamily IVF, polypeptide 12
Modification date2020031320200313
UniProtAcc

O60762

Main function of 5'-partner protein: FUNCTION: Transfers mannose from GDP-mannose to dolichol monophosphate to form dolichol phosphate mannose (Dol-P-Man) which is the mannosyl donor in pathways leading to N-glycosylation, glycosyl phosphatidylinositol membrane anchoring, and O-mannosylation of proteins; catalytic subunit of the dolichol-phosphate mannose (DPM) synthase complex.

Q9HCS2

Main function of 5'-partner protein: FUNCTION: A cytochrome P450 monooxygenase involved in the metabolism of endogenous polyunsaturated fatty acids (PUFAs). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase). Catalyzes the hydroxylation of carbon hydrogen bonds, with preference for omega-2 position. Metabolizes (5Z,8Z,11Z,14Z)-eicosatetraenoic acid (arachidonate) toward 18-hydroxy arachidonate (PubMed:11162607). Catalyzes the epoxidation of double bonds of PUFAs such as docosapentaenoic and docosahexaenoic acids (PubMed:16112640). Has low omega-hydroxylase activity toward leukotriene B4 and arachidonate (PubMed:11162645). Involved in the metabolism of xenobiotics. Catalyzes the hydroxylation of the antihistamine drug ebastine (PubMed:11162645). {ECO:0000269|PubMed:11162607, ECO:0000269|PubMed:11162645, ECO:0000269|PubMed:16112640}.
Ensembl transtripts involved in fusion geneENST idsENST00000466152, ENST00000371582, 
ENST00000371583, ENST00000371588, 
ENST00000324632, ENST00000550308, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score11 X 8 X 6=5281 X 1 X 1=1
# samples 131
** MAII scorelog2(13/528*10)=-2.02202630633
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(1/1*10)=3.32192809488736
Fusion gene context

PubMed: DPM1 [Title/Abstract] AND CYP4F12 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: DPM1 [Title/Abstract] AND CYP4F12 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)DPM1(49571723)-CYP4F12(15807240), # samples:3
Anticipated loss of major functional domain due to fusion event.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneDPM1

GO:0006506

GPI anchor biosynthetic process

9535917|9724629|10835346

HgeneDPM1

GO:0019348

dolichol metabolic process

9535917|9724629

HgeneDPM1

GO:0035268

protein mannosylation

9535917

HgeneDPM1

GO:0035269

protein O-linked mannosylation

9535917



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr20:49571723/chr19:15807240)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across DPM1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across CYP4F12 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000371588DPM1chr2049571723-ENST00000550308CYP4F12chr1915807240+63828827548173
ENST00000371588DPM1chr2049571723-ENST00000324632CYP4F12chr1915807240+60928827548173
ENST00000371582DPM1chr2049571723-ENST00000550308CYP4F12chr1915807240+64329332553173
ENST00000371582DPM1chr2049571723-ENST00000324632CYP4F12chr1915807240+61429332553173
ENST00000371583DPM1chr2049571723-ENST00000550308CYP4F12chr1915807240+6202709530173
ENST00000371583DPM1chr2049571723-ENST00000324632CYP4F12chr1915807240+5912709530173

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000371588ENST00000550308DPM1chr2049571723-CYP4F12chr1915807240+0.0065775620.99342245
ENST00000371588ENST00000324632DPM1chr2049571723-CYP4F12chr1915807240+0.0058489770.99415106
ENST00000371582ENST00000550308DPM1chr2049571723-CYP4F12chr1915807240+0.0055743460.99442565
ENST00000371582ENST00000324632DPM1chr2049571723-CYP4F12chr1915807240+0.0047889060.99521106
ENST00000371583ENST00000550308DPM1chr2049571723-CYP4F12chr1915807240+0.0065247050.99347526
ENST00000371583ENST00000324632DPM1chr2049571723-CYP4F12chr1915807240+0.0057109630.99428904

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for DPM1-CYP4F12

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
DPM1chr2049571723CYP4F12chr191580724027087AEQLEKIYGSDRIVYDPFRFDPENSK
DPM1chr2049571723CYP4F12chr191580724028887AEQLEKIYGSDRIVYDPFRFDPENSK
DPM1chr2049571723CYP4F12chr191580724029387AEQLEKIYGSDRIVYDPFRFDPENSK

Top

Potential FusionNeoAntigen Information of DPM1-CYP4F12 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
DPM1-CYP4F12_49571723_15807240.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
DPM1-CYP4F12chr2049571723chr1915807240293HLA-A32:13RIVYDPFRF0.95540.80121120
DPM1-CYP4F12chr2049571723chr1915807240293HLA-B15:01KIYGSDRIVY0.99940.7436515
DPM1-CYP4F12chr2049571723chr1915807240293HLA-B15:25KIYGSDRIVY0.99820.7279515
DPM1-CYP4F12chr2049571723chr1915807240293HLA-C15:04IVYDPFRF0.99880.80171220
DPM1-CYP4F12chr2049571723chr1915807240293HLA-C07:67IYGSDRIVY0.40110.7735615
DPM1-CYP4F12chr2049571723chr1915807240293HLA-C07:80IYGSDRIVY0.40110.7735615
DPM1-CYP4F12chr2049571723chr1915807240293HLA-C07:10IYGSDRIVY0.37870.8204615
DPM1-CYP4F12chr2049571723chr1915807240293HLA-C07:27IYGSDRIVY0.35850.8086615
DPM1-CYP4F12chr2049571723chr1915807240293HLA-C07:46IYGSDRIVY0.33710.5876615
DPM1-CYP4F12chr2049571723chr1915807240293HLA-B15:04KIYGSDRIVY0.98840.7353515
DPM1-CYP4F12chr2049571723chr1915807240293HLA-B15:05KIYGSDRIVY0.96710.6461515
DPM1-CYP4F12chr2049571723chr1915807240293HLA-C03:02IVYDPFRF0.99940.91551220
DPM1-CYP4F12chr2049571723chr1915807240293HLA-C15:09IVYDPFRF0.99880.80171220
DPM1-CYP4F12chr2049571723chr1915807240293HLA-C16:01YGSDRIVY0.97280.9156715
DPM1-CYP4F12chr2049571723chr1915807240293HLA-A32:01RIVYDPFRF0.98150.87651120
DPM1-CYP4F12chr2049571723chr1915807240293HLA-C07:02IYGSDRIVY0.40110.7735615
DPM1-CYP4F12chr2049571723chr1915807240293HLA-C07:17IYGSDRIVY0.38250.8603615
DPM1-CYP4F12chr2049571723chr1915807240293HLA-C14:02IYGSDRIVY0.05560.813615
DPM1-CYP4F12chr2049571723chr1915807240293HLA-C14:03IYGSDRIVY0.05560.813615
DPM1-CYP4F12chr2049571723chr1915807240293HLA-B15:34KIYGSDRIVY0.99940.7436515
DPM1-CYP4F12chr2049571723chr1915807240293HLA-B15:125KIYGSDRIVY0.99940.7436515
DPM1-CYP4F12chr2049571723chr1915807240293HLA-B15:33KIYGSDRIVY0.99940.7436515
DPM1-CYP4F12chr2049571723chr1915807240293HLA-B15:27KIYGSDRIVY0.99940.7593515
DPM1-CYP4F12chr2049571723chr1915807240293HLA-B15:50KIYGSDRIVY0.99940.6155515
DPM1-CYP4F12chr2049571723chr1915807240293HLA-B15:135KIYGSDRIVY0.99920.7509515
DPM1-CYP4F12chr2049571723chr1915807240293HLA-B15:39KIYGSDRIVY0.99840.572515
DPM1-CYP4F12chr2049571723chr1915807240293HLA-B15:12KIYGSDRIVY0.99820.6674515
DPM1-CYP4F12chr2049571723chr1915807240293HLA-B15:35KIYGSDRIVY0.99810.6565515
DPM1-CYP4F12chr2049571723chr1915807240293HLA-B15:20KIYGSDRIVY0.96720.7353515
DPM1-CYP4F12chr2049571723chr1915807240293HLA-B35:28KIYGSDRIVY0.95210.7366515
DPM1-CYP4F12chr2049571723chr1915807240293HLA-A32:01KIYGSDRIVY0.94710.6005515

Top

Potential FusionNeoAntigen Information of DPM1-CYP4F12 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
DPM1-CYP4F12_49571723_15807240.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-0307QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-0307LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-0315QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-0315LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-0324QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-0324LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-0409EKIYGSDRIVYDPFR419
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1107QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1107LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1113LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1113QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1117QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1117LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1152QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1152LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1331QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1331LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1343QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1343LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1354QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1354LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1376QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1376LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1377QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1377LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1401QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1401LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1404QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1404LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1405QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1405LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1407QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1408QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1408LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1411QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1411LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1416QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1416LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1418QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1418LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1421QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1421LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1423QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1423LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1426QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1426LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1428QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1428LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1428EKIYGSDRIVYDPFR419
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1428EQLEKIYGSDRIVYD116
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1431QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1432QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1432LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1433QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1433LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1435QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1435LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1435EQLEKIYGSDRIVYD116
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1435EKIYGSDRIVYDPFR419
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1438QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1438LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1438EKIYGSDRIVYDPFR419
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1443QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1443LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1445QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1445LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1450QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1450LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1454QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1454LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1455QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1455LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1456QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1456LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1458QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1458LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1459QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1459LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1460QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1460LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1461QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1461LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1462QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1462LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1462EKIYGSDRIVYDPFR419
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1462EQLEKIYGSDRIVYD116
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1464QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1464LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1464EKIYGSDRIVYDPFR419
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1465QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1465LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1470QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1470LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1471QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1471LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1472QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1472LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1472EKIYGSDRIVYDPFR419
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1475QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1475LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1482QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1482LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1482EQLEKIYGSDRIVYD116
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1482EKIYGSDRIVYDPFR419
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1486QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1486LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1487QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1487LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1488QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1488LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1490QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1490LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1491QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1491LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1495QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1495LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1495EKIYGSDRIVYDPFR419
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1495EQLEKIYGSDRIVYD116
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1496QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1496LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1497QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1497LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1499QLEKIYGSDRIVYDP217
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1499LEKIYGSDRIVYDPF318
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1499EQLEKIYGSDRIVYD116
DPM1-CYP4F12chr2049571723chr1915807240293DRB1-1499EKIYGSDRIVYDPFR419

Top

Fusion breakpoint peptide structures of DPM1-CYP4F12

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
4079IYGSDRIVYDPFRFDPM1CYP4F12chr2049571723chr1915807240293

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of DPM1-CYP4F12

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN4079IYGSDRIVYDPFRF-6.00367-7.03897
HLA-B14:023BVN4079IYGSDRIVYDPFRF-5.39279-5.50619
HLA-B52:013W394079IYGSDRIVYDPFRF-6.37513-6.48853
HLA-B52:013W394079IYGSDRIVYDPFRF-5.71942-6.75472
HLA-A11:014UQ24079IYGSDRIVYDPFRF-11.5708-11.6842
HLA-A11:014UQ24079IYGSDRIVYDPFRF-8.11091-9.14621
HLA-A24:025HGA4079IYGSDRIVYDPFRF-6.75661-6.87001
HLA-A24:025HGA4079IYGSDRIVYDPFRF-5.30147-6.33677
HLA-B27:056PYJ4079IYGSDRIVYDPFRF-4.27108-5.30638
HLA-B44:053DX84079IYGSDRIVYDPFRF-6.47731-6.59071
HLA-B44:053DX84079IYGSDRIVYDPFRF-3.23433-4.26963

Top

Vaccine Design for the FusionNeoAntigens of DPM1-CYP4F12

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
DPM1-CYP4F12chr2049571723chr19158072401120RIVYDPFRFAGAATTGTCTACGACCCCTTCCGCTTT
DPM1-CYP4F12chr2049571723chr19158072401220IVYDPFRFATTGTCTACGACCCCTTCCGCTTT
DPM1-CYP4F12chr2049571723chr1915807240515KIYGSDRIVYAAGATCTATGGGTCAGACAGAATTGTCTAC
DPM1-CYP4F12chr2049571723chr1915807240615IYGSDRIVYATCTATGGGTCAGACAGAATTGTCTAC
DPM1-CYP4F12chr2049571723chr1915807240715YGSDRIVYTATGGGTCAGACAGAATTGTCTAC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
DPM1-CYP4F12chr2049571723chr1915807240116EQLEKIYGSDRIVYDGAACAGTTGGAGAAGATCTATGGGTCAGACAGAATTGTCTACGAC
DPM1-CYP4F12chr2049571723chr1915807240217QLEKIYGSDRIVYDPCAGTTGGAGAAGATCTATGGGTCAGACAGAATTGTCTACGACCCC
DPM1-CYP4F12chr2049571723chr1915807240318LEKIYGSDRIVYDPFTTGGAGAAGATCTATGGGTCAGACAGAATTGTCTACGACCCCTTC
DPM1-CYP4F12chr2049571723chr1915807240419EKIYGSDRIVYDPFRGAGAAGATCTATGGGTCAGACAGAATTGTCTACGACCCCTTCCGC

Top

Information of the samples that have these potential fusion neoantigens of DPM1-CYP4F12

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
OVDPM1-CYP4F12chr2049571723ENST00000371582chr1915807240ENST00000324632TCGA-13-0923-01A

Top

Potential target of CAR-T therapy development for DPM1-CYP4F12

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to DPM1-CYP4F12

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to DPM1-CYP4F12

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource